Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have gained monotherapy approval for advanced colorectal cancers exhibiting mismatch repair deficiency (dMMR) and/or high microsatellite instability (MSI-H) (44–46). The gene discussed is CD274; the disease is colorectal cancer.